| |
Re mood: IR did not return call or send email. QED
Re: Inhalant => will it cannibalize sales of their other inhalants? How much market share will they gain? What will be the price relative to CFC inhalants on the market? Since CFC-free is not mandated, people won't switch unless the price is right. Can the price be right? Probably not or we would have been told so. We apparently are never told the bad news (except for lousy earnings). The market didn't much care for the news.
Since I bought into this dog at $9/sh, Ivax has had some news:
Paxene FDA panel approval
restructuring and cost savings (I hope Bethune has eliminated IR dept)
asset sales
debt extinguishment
CFC-free inhalant approval Europe
increase stake in Galena
And now the stock is at $7/sh, while the market has pretty much traded sideways. What is going on?
a) The shorts increase their position monthly;
b) Book value dropping like a rock has probably scared some big money out, probably those funds you outlined several posts ago.
On the dim side, it appears that the $7 area brings some pretty heavy buying; however, that surely doesn't preclude a move to $6 1/2 which I await any day now. I can't find a bright side.
Sincerely,
Kamekaze Investor,
Jackson |
|
